Eosinophilic Granuloma (Histiocytosis X) Medication
- Author: Eleanor M Summerhill, MD, FACP, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP more...
The mainstays of treatment for pulmonary Langerhans cell histiocytosis X (PLCH) are smoking cessation and supportive therapy. The use of corticosteroids in the treatment of PLCH is controversial. Their efficacy has not been proven in well-designed, prospective, randomized, controlled trials. Some experts recommend a trial of corticosteroids for those patients with persistent symptomatic disease or evidence of progression.
Patients with an obstructive ventilatory defect on pulmonary function testing may benefit from bronchodilator therapy.
Supplemental oxygen therapy is indicated for all patients with either resting or exertional hypoxemia. Oxygen therapy may help to prevent or slow progression of pulmonary hypertension and cor pulmonale, and it provides a mortality benefit in chronic obstructive pulmonary disease.
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli.
Prednisone is used as an immunosuppressant to treat autoimmune disorders. By reversing increased capillary permeability and suppressing the activity of polymorphonuclear cells, it may decrease inflammation. Prednisone is an oral corticosteroid with relatively limited mineralocorticoid activity. It is best prescribed in consultation with a pulmonary disease specialist.
Podbielski FJ, Worley TA, Korn JM, Connolly MM. Eosinophilic granuloma of the lung and rib. Asian Cardiovasc Thorac Ann. 2009 Apr. 17(2):194-5. [Medline].
Szturz P, Rehak Z, Koukalova R, Adam Z, Mayer J. FDG-PET positive pilomatrixoma--reconsidering multicentricity in Langerhans cell histiocytosis. Nucl Med Rev Cent East Eur. 2014. 17(2):94-6. [Medline].
Gaensler EA, Carrington CB. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic, and physiological correlations in 502 patients. Ann Thorac Surg. 1980 Nov. 30(5):411-26. [Medline].
Colby TV, Lombard C. Histiocytosis X in the lung. Hum Pathol. 1983 Oct. 14(10):847-56. [Medline].
Thomeer M, Demedts M, Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001 May-Jun. 56(3):163-72. [Medline].
Watanabe R, Tatsumi K, Hashimoto S, Tamakoshi A, Kuriyama T. Clinico-epidemiological features of pulmonary histiocytosis X. Intern Med. 2001 Oct. 40(10):998-1003. [Medline].
Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 2002 Feb 14. 346(7):484-90. [Medline].
Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord. Eur Respir J. 1996 Oct. 9(10):2002-6. [Medline].
DiCaprio MR, Roberts TT. Diagnosis and Management of Langerhans Cell Histiocytosis. J Am Acad Orthop Surg. 2014 Oct. 22(10):643-652. [Medline].
Stacher E, Beham-Schmid C, Terpe HJ, Simiantonaki N, Popper HH. Pulmonary histiocytic sarcoma mimicking pulmonary Langerhans cell histiocytosis in a young adult presenting with spontaneous pneumothorax: a potential diagnostic pitfall. Virchows Arch. 2009 Aug. 455(2):187-90. [Medline].
Alalawi R, Whelan T, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med. 2005 Sep. 11(5):461-6. [Medline].
Misaki H, Yamauchi T, Arai H, et al. Secondary malignant fibrous histiocytoma following refractory langerhans cell histiocytosis. J Clin Exp Hematop. 2009 May. 49(1):33-7. [Medline].
Harari S, Torre O, King Jr TE, Moss J. Pulmonary Langerhans' Cell Histiocytosis. Elias JA, Fishman JA, Kotloff RM, Pack A, Senior RM, eds. Fishman's Pulmonary Diseases and Disorders. 5th ed. New York, NY: McGraw-Hill; 2015. 919-27.